<DOC>
	<DOCNO>NCT00880893</DOCNO>
	<brief_summary>Primary Objectives : - To evaluate safety CYD Dengue vaccination . - To evaluate immune response CYD Dengue serotype vaccination subset subject .</brief_summary>
	<brief_title>Study Sanofi Pasteur 's CYD Dengue Vaccine Healthy Subjects Singapore</brief_title>
	<detailed_description>This multicenter trial involve three vaccination period 1 year , 4-year follow-up follow last vaccination .</detailed_description>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Hemorrhagic Fevers , Viral</mesh_term>
	<mesh_term>Severe Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Aged 2 45 year day inclusion . Subject good health , base medical history physical examination . Provision informed consent form ( assent form subject age 6 12 year ) sign subject parent ( ) another legally acceptable representative subject age less 21 year . Subject parent ( ) /legally acceptable representative able attend schedule visit comply trial procedure . For woman childbearing potential , avoid become pregnant ( use effective method contraception abstinence ) least 4 week first vaccination 4 week last vaccination . Exclusion Criteria : Febrile illness ( temperature ≥ 37.5°C ) moderate severe acute illness/infection day first vaccination , accord Investigator judgment . For woman childbearing potential , known pregnancy positive urine pregnancy test day inclusion . Breastfeeding woman . Known systemic hypersensitivity component trial vaccine ( especially egg protein neomycin ) history lifethreatening reaction trial vaccine vaccine contain substance . Personal family history thymic pathology myasthenia . Previous hepatitis A vaccination ( child ) . Known suspected congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within past 6 month , longterm systemic corticosteroid therapy . Chronic illness stage could interfere trial conduct completion , opinion Investigator . Receipt blood bloodderived product past 3 month might interfere assessment immune response . Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede first trial vaccination . Planned participation another clinical trial 18 coming month . Receipt vaccine 4 week precede first trial vaccination . Planned receipt vaccine 4 week follow first trial vaccination . Subject deprive freedom administrative court order , emergency setting , hospitalize without his/her consent . Current past alcohol abuse drug addiction may interfere subject 's ability comply trial procedure . Subject plan move another country within 18 coming month .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Dengue virus</keyword>
	<keyword>Dengue fever</keyword>
	<keyword>Dengue hemorrhagic fever</keyword>
	<keyword>Dengue disease</keyword>
	<keyword>Sanofi Pasteur 's CYD Dengue Vaccine</keyword>
</DOC>